Chemomab Therapeutics to Present at Upcoming Scientific Conferences
- Chemomab Therapeutics will present at major U.S. scientific conferences in November, including an oral presentation on primary sclerosing cholangitis and a poster on the role of CCL24 target in manifestations of systemic sclerosis. These presentations provide an opportunity for the company to showcase its innovative therapeutics for fibro-inflammatory diseases, potentially attracting investor interest and positively impacting the stock price.
- None.
AASLD The Liver Meeting® 2023,
Date: | Nov. 13, 2023 |
Time: | 4:30pm ET |
Format: | Oral presentation: Serum proteomics reveals unique association of CCL24 with disease-related pathways and signatures in primary sclerosing cholangitis |
Presenter: | Ilan Vaknin, PhD, Vice President of R&D, Chemomab Therapeutics, Ltd. |
Authors: | Tom Snir, Raanan Greenman, Revital Aricha, John Lawler, Francesca Saffioti, Douglas Thorburn, Massimo Pinzani, Adi Mor, Ilan Vaknin |
Session: | Room 312 - Breaking the Chains of Cholestatic Liver Injury: Advancements and Promising Treatment Strategies |
Information: |
AASLD The Liver Meeting® 2023,
Date: | Nov. 11, 2023 |
Time: | 1:00-2:00 pm ET |
Format: | Poster presentation: CM-101, a CCL24 neutralizing antibody, showed improvements in inflammatory, fibrotic, and metabolic pathways in patients with NASH: Proteomics analysis of a Phase 2a study |
Presenter: | Matt Frankel, MD, Chief Medical Officer & Vice President of Drug Development, Chemomab Therapeutics |
Authors: | Revital Aricha, Tom Snir, Ilan Vaknin, John Lawler, Adi Mor, Matt Frankel |
Session: | Poster session Hall C – 2nd level |
Information: |
American College of Rheumatology Convergence 2023 –
Date: | Nov. 14, 2023 |
Time: | 9:00-11:00 am PT |
Format: | Poster presentation: The Involvement of CCR3-CCL24 Axis in Endothelial to Mesenchymal Transition Process and Pulmonary Arterial Hypertension in Systemic Sclerosis Patients |
Presenter: | Ilan Vaknin, PhD, Vice President of R&D, Chemomab Therapeutics |
Authors: | Itzchak Amoyal, Tzipi Hornik-Lurie, Tali Zitman-Gal, Hilit Levy, Ilan Vaknin Liat Drucker, Ishai Heusler, Yair Levy, Shelly Tartakover Matalo |
Session: | Poster Session C, Systemic Sclerosis & Related Disorders – Clinical Poster III: Translational Science |
Information: |
About Chemomab Therapeutics Ltd.
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to neutralize CCL24 activity. In preclinical and clinical studies, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported encouraging results from three clinical trials of CM-101 in patients, including a Phase 1b trial in NAFLD patients, a Phase 2a liver fibrosis trial in NASH patients and an investigator-initiated study in patients with severe lung injury. The CM-101 program for the treatment of systemic sclerosis is Phase 2-ready and a Phase 2 trial in primary sclerosing cholangitis patients is ongoing, with topline data expected in the second half of 2024. For more information about Chemomab, visit chemomab.com.
Contacts:
Media and Investors:
Barbara Lindheim
Consulting Vice President, Investor & Public Relations,
Strategic Communications
Phone: +1 917-355-9234
barbara.lindheim@chemomab.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-present-at-upcoming-scientific-conferences-301968462.html
SOURCE Chemomab Therapeutics, Ltd.
FAQ
What conferences will Chemomab Therapeutics present at in November?
What topics will be covered in the presentations?
Who will be presenting at the conferences?
